
News
First European commercial ROCTAVIAN treatment takes place in Germany
BioMarin Pharmaceutical Inc, a global biotechnology company, announced that an individual in Germany with severe haemophilia A was treated with ROCTAVIAN (valoctocogene roxaparvovec-rvox), marking the first time that the gene therapy has been given commercially in Europe.